Mobile

A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate Re...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011206-42

A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate Response to Any Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy including Biologics

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The Primary Objectives of this study are to determine the: • Safety and tolerability of 3 months of dosing of INCB028050 in patients with active rheumatoid arthritis who have had inadequate response to any DMARD therapy. • Efficacy of INCB028050 at 3 months in patients with active rheumatoid arthritis who have had inadequate response to any DMARD therapy.

Critère d'inclusion

  • active rheumatoid arthritis

Liens